The discovery of biomarkers to predict the potential for lymph node (LN) metastasis in patients with colorectal cancer (CRC) is essential for developing improved strategies for treating CRC. In the present study, they used isobaric tags for relative and absolute quantitation to conduct a proteomic analysis designed to identify novel biomarkers for predicting LN metastasis in patients with CRC. They identified 60 differentially expressed proteins specifically associated with LN metastasis in CRC patients and classified the molecular and functional characteristics of these proteins by bioinformatic approaches. A literature search led them to select heat shock protein 47 (HSP47) as the most suitable candidate biomarker for predicting LN metastasis. Validation analysis by immunohistochemistry showed that HSP47 expression in patients with CRC and the number of HSP47-positive spindle cells in the tumor stroma were significantly higher compared with those in adjacent normal colonic mucosa, and the number of the latter cells increased with tumor progression. Further, the number of HSP47-positive spindle cells in stroma was a more informative marker for identifying LN metastasis than HSP47expression. Multivariate analysis identified spindle cells that expressed elevated levels of HSP47 as an independent predictive biomarker for CRC with LN metastasis. Moreover, these cells served as an independent marker of disease-free and overall survival of patients with CRC. Their data indicate that the number of HSP47-positive spindle cells in the stroma of CRC may serve as a novel predictive biomarker of LN metastasis, early recurrence and poor prognosis.
The discovery of biomarkers to predict the potential for lymph node (LN) metastasis in patients with colorectal cancer (CRC) is essential for developing improved strategies for treating CRC. In the present study, they used isobaric tags for relative and absolute quantitation to conduct a proteomic analysis designed to identify novel biomarkers for predicting LN metastasis in patients with CRC. They identified 60 differentially expressed proteins specifically associated with LN metastasis in CRC patients and classified the molecular and functional characteristics of these proteins by bioinformatic approaches. A literature search led them to select heat shock protein 47 (HSP47) as the most suitable candidate biomarker for predicting LN metastasis. Validation analysis by immunohistochemistry showed that HSP47 expression in patients with CRC and the number of HSP47-positive spindle cells in the tumor stroma were significantly higher compared with those in adjacent normal colonic mucosa, and the number of the latter cells increased with tumor progression. Further, the number of HSP47-positive spindle cells in stroma was a more informative marker for identifying LN metastasis than HSP47expression. Multivariate analysis identified spindle cells that expressed elevated levels of HSP47 as an independent predictive biomarker for CRC with LN metastasis. Moreover, these cells served as an independent marker of disease-free and overall survival of patients with CRC. Their data indicate that the number of HSP47-positive spindle cells in the stroma of CRC may serve as a novel predictive biomarker of LN metastasis, early recurrence and poor prognosis.
Colorectal cancer (CRC) is the second most common cancer and fourth leading cause of cancer-related deaths worldwide. 1 Surgical resection is the only cure for CRC, particularly for patients with confined disease. Curative surgical resection typically involves primary, standardized and systematic dissection of all potentially affected lymph nodes (LNs) to determine the extent of bowel resection. A recent metaanalysis revealed histopathological features of primary CRC that can predict LN metastasis as follows (in descending order of importance): lymphatic invasion, tumor depth, poor tumor differentiation and tumor budding. 2 However, these of resected tumor specimens after surgery. Therefore, the development of tools for accurate preoperative detection of LN metastasis is important in improving their clinical management using modalities such as minimum surgery or neoadjuvant chemotherapy. Noninvasive imaging techniques that are frequently used for the preoperative diagnosis of LN metastasis in patients with CRC include computed tomography (CT), magnetic resonance imaging (MRI) and endorectal ultrasonography (EUS). The sensitivities of CT, MRI imaging and EUS are 55, 66 and 66%, respectively, and their respective specificities are 74, 76 and 78%. 3, 4 Moreover, preoperative biomarkers such as the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9) as well as systemic inflammatory-response markers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio have the potential to act as supplemental tools for improvement of the classification of LN metastasis in patients with CRC. [5] [6] [7] [8] [9] However, none of these markers are recommended for routine screening because of insufficient sensitivity and specificity. Recent advances in proteomic technologies led to the discovery of novel proteins associated with cancer incidence and progression. 10, 11 In the present study, we first used the isobaric tag for relative and absolute quantification (iTRAQ) method to identify proteins associated with LN metastasis in patients with CRC. To validate these proteins as specific biomarkers, we next used immunohistochemistry (IHC) to determine their expression levels in CRC tissues and the adjacent normal colonic mucosa. We used a bioinformatics approach to determine that heat shock protein 47 (HSP47) was the most suitable potential biomarker and validated its utility through further analysis of patients' survival rates and tumor phenotypes.
Material and Methods

Samples
To identify differentially expressed proteins, we designed a biomarker discovery set comprising of 20 clinical specimens from the patients. The samples were comprised of the following: CRC with LN metastasis (stage III, n 5 5); CRC without LN metastasis (stage II, n 5 5); CRC, adjacent normal mucosae from CRC patient (n 5 5) and normal colorectal mucosae from benign colorectal disease (n 5 5). All samples were collected from resected specimens and were immediately immersed in liquid nitrogen and stored at 2808C. The pathological T classification of all CRC samples was the SS stage. None of the patients underwent preoperative radiotherapy, chemotherapy or both. Next, we prepared 33 independent specimens to verify whether candidate protein was elevated in CRC with LN metastasis by western blot analysis. The samples consisted of the following: CRC with LN metastasis (stage III, n 5 11); CRC without LN metastasis (stage I-II, n 5 11) and adjacent normal mucosae from CRC patients (n 5 11). Moreover, for the validation study by IHC, we enrolled 157 patients with CRC (90 men, 67 women) who were treated with curative intent at the Mie University Medical Hospital, Japan between January 1, 2006, and December 31, 2011. Exclusion criteria included inflammatory bowel disease, familial adenomatous polyposis, hereditary nonpolyposis colon cancer, or other rare and complex tumors. The mean age of the patients was 67 years (range, 35-89 years). Patients did not receive chemotherapy or radiotherapy before surgery, and perioperative mortality did not occur.
All patients with CRC were classified according to the tumor-node-metastasis (TNM) classification system as follows: stage I, n 5 48; stage II, n 5 56 and stage III, n 5 53. The median follow-up was 20.7 months (range, 1-62 months). The Mie University Hospital Ethical Review Committee approved the research protocol, and participants provided written informed consent and granted their approval to donate clinical samples.
Protein extraction and preparation procedures
Frozen samples were weighed (6-20 mg), homogenized using a TissueLyser II (Qiagen, Tokyo, Japan), and kept frozen on dry ice. Lysis buffer (50 mM ammonium bicarbonate, 50 mM dithiothreitol and 0.5% sodium deoxycholate [SDC]) containing a protease inhibitor cocktail was added, and samples were homogenized on ice using an Ultrasonic Disruptor (TOMY) with 20 10-sec pulses. Samples were centrifuged for 10 min at 130,000g, and the supernatants were mixed with five volumes of acetone (stored at 2208C) and incubated overnight at 2208C. Precipitated proteins were centrifuged for 15 min at 160,000g. The protein pellets, which were not air-dried, were resuspended in 0.5 M triethylammonium bicarbonate (TEAB) containing 0.5% SDC. The protein What's new? Preoperative biomarkers can potentially facilitate the classification of lymph node metastases from colorectal cancer (CRC) patients. Limited sensitivity and specificity, however, prevents their use in routine screening to predict CRC spread to the lymph nodes. In an effort to discover new biomarkers, the authors of this study performed proteomic analysis using isobaric tags for relative and absolute quantification (iTRAQ). The methodology led to the identification of heat shock protein 47 (HSP47) as a novel predictor of CRC lymph node metastasis. Tumor progression, recurrence, and patient prognosis were associated specifically with the number of HSP47-positive spindle cells in the tumor stroma.
concentration of each sample was determined using the bicinchoninic acid assay (catalog #23227, Pierce). Protein extracts were stored as aliquots at 2808C.
iTRAQ labeling
A total of 100 mg of protein per group was labeled using an iTRAQ kit (AB SCIEX, Foster City, CA). TEAB and SDC were added to each sample to final concentrations of 0.5 M and 0.5% (w/v), respectively. Proteins were reduced and alkylated according to the manufacturer's instructions. Samples were digested with trypsin (1:30 [w/w], sequence grade modified; Promega) overnight at 378C. The iTRAQ 4-plex reagents (Applied Biosystems, Foster City, CA) were used to label the samples as follows: CRC with LN metastasis group (iTRAQ reagent 114); CRC without LN metastasis group (iTRAQ reagent 117); CRC adjacent group (iTRAQ reagent 115); and healthy control group (iTRAQ reagent 116). The four sample groups were mixed and incubated for 1 hr at room temperature. Potentially interfering substances were removed using a cation-exchange cartridge system (catalog # 4326747, AB SCIEX) according to the manufacturer's instructions. The ion-exchange eluate was desalted using a Sep-Pak C18 cartridge (Agilent, Palo Alto, MA). The peptides generated from each sample were analyzed using a QTRAP5500 (AB SCIEX, Foster City, CA), and data analysis was performed using ProteinPilot software (AB SCIEX).
Western blot analysis
Frozen samples and cells were homogenized in lysis buffer for 5 min on ice. Thereafter, the supernatants were collected after centrifugation for 10 min at 130,000g at 48C and protein concentration was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Science, Rockford, IL). Lysates containing 1 mg total protein were mixed with appropriate quantities of Laemmle's loading buffer containing b-mercaptoethanol and denatured by hearting at 1008C for 5 min. Samples were electrophoretically separated on 15.0% gradient polyacrylamide gels containing 0.1% sodium dodecyl sulfate, followed by semi-dry transfer to an Immuno-Blot PVDF membrane (Bio-Rad Laboratories, Hercules, CA). The membranes were then blocked for 30 min at room temperature with Blocking One (#03953-95, Nacalai Tesque, Kyoto, Japan). The blots were incubated with a mouse monoclonal antibody against HSP47 (diluted 1:500; M16.10A1, ADI-SPA-470; Enzo Life Sciences) and a mouse monoclonal antibody against b-actin (diluted 1:400; C4;Mp biomedicals) diluted in Blocking one at 48C overnight. After washing three times with Tris Buffered Saline with Tween 20 (TBS-T), the blot were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG antibody (diluted 1:2500; Promega) diluted in Blocking one. Following treatment with an enhanced chemiluminescence detection solution, Pierce Western Blotting Substrate Plus (Thermo Fisher Scientific), chemiluminescent signals were visualized in a CS Analyzer and AE-6962 light capture (ATTO, Tokyo, Japan).
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded (FFPE) sections (3 mm thick) were prepared from surgical specimens of patients with CRC. After deparaffinization and dehydration, the sections were placed in 10 mM sodium citrate buffer (pH 6.0) and autoclaved at 1218C for 10 min for epitope retrieval. The sections were incubated in 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity and then incubated in normal goat serum (Vector Laboratories Inc., Burlingame, CA) for 1 hr to block any nonspecific antibody-binding sites. After incubation in blocking solutions, the sections were incubated with an antibody against HSP47 (diluted 1:200; M16.10A1, ADI-SPA-470; Enzo Life Sciences) at 48C overnight. Antibody binding was detected using Envision reagents (Dako REAL EnVision Detection System; peroxidase/DAB1, Dako Cytomation, Denmark). Sections were counterstained using hematoxylin-eosin before dehydration and mounting. 
HSP47 expression scores
Quantitation of HSP47-positive stromal spindle cells
The number of stromal spindle cells that reacted with the anti-HSP47 antibody were counted using a Biorevo BZ-9000 microscope (Keyence, Osaka, Japan) equipped with an image scanning system, and images of cells in three representative fields were acquired at 4003 magnification. Spindle cells with HSP47 staining above background levels were considered positive (Supporting Information Figs. 3A-3D).
Definition of tumor budding
Tumor budding, which was determined according to published methods, 12, 13 was defined as a single cancer cell or clusters of <5 cancer cells in the invasive frontal region. To determine the degree of tumor budding, the clusters were counted at 2003 magnification in a field with numerous buds. Tumors with <5, 5-9 and 10 budding foci were classified as Grades 1, 2 and 3, respectively.
Tumor Markers and Signatures
Analysis of KRAS and BRAF mutations and microsatellite instability (MSI)
FFPE sections (10 mm thick) from 157 surgical specimens acquired from patients with CRC were analyzed for KRAS and BRAF mutations. Genomic DNA was extracted from hematoxylin-eosin-stained FFPE sections using the QIAamp DNA FFPE Tissue Kit (Qiagen) according to the manufacture's protocol. DNA quantity and quality were assessed using a NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Houston, TX). KRAS (exons 2 and 3) and the BRAF (V600E) mutation were analyzed using pyrosequencing with the primers listed in Supporting Information Table 1 .
Reactions were performed using a PyroMark Q96 ID System (Qiagen). MSI was determined using the polymerase chain reaction and five mononucleotide-repeat microsatellite markers (BAT-25, BAT-26, NR-21, NR-24 and NR-27), as recommended previously. 14 The primer sequences are published. 14 Tumors with instability at more than three of these markers or fewer than two markers were classified as MSI or microsatellite stability (MSS), respectively.
Statistical analysis
Statistical analyses were performed using JMP version 10 (SAS Institute, Cary, NC). The results were expressed as the mean 6 standard deviation (SD). Comparisons were performed using the nonparametric Mann-Whitney test for continuous variables. Differences between groups were estimated using Pearson's v2 test or Fisher's exact probability test. Receiver operating characteristic (ROC) curves were generated to determine cutoff values for predicting LN metastasis and prognosis, which were analyzed using Youden's index. The Kaplan-Meier method was used to determine the cumulative probability of overall survival (OS) and disease-free survival (DFS), and the differences were evaluated using logrank tests. Prognostic factors were evaluated using univariate and multivariate analysis (Cox proportional hazards regression model). Logistic regression analysis was used to evaluate the factors influencing LN metastasis. A value of p < 0.05 was considered statistically significant.
Results
Identification and quantitation of differentially expressed proteins
A summary of the workflow used for relative quantification of iTRAQ data is shown in Supporting Information Figure 4 . The four groups compared were CRC with (n 5 5) and without LN metastasis (n 5 5), adjacent normal colonic mucosa (n 5 5), and normal colonic mucosa (n 5 5) (labeled as 114, 117, 115 and 116 iTRAQ reagents, respectively). Following completion of the experimental protocol and data analysis with ProteinPilot software, we identified a total of 4000 proteins differentially expressed between the four groups. From these, we selected 60 proteins using a ratio of 117:114 tags <0.5, and the ratios of 116:114 and 115:114 were less than that of 117:114. The detailed list of candidate proteins is shown in Supporting Information Table 2 . Next, we classified 60 differentially expressed proteins associated with CRC tissue with LN metastasis using the Protein Analysis through Evolutionary Relationship Classification System (www.pantherdb.org) to identify their molecular and functional characteristics. These analyses classified 16, 8 and 11 proteins into biological processes, cellular components and molecular functions, respectively (Supporting Information Figs. 5A-5C ). The most frequent biological process categories were metabolic (25.7%), cellular (20.9%) and biological regulation (12.2%) (Supporting Information Fig. 5A ). The three most frequent cellular component categories were cell (38.6%), organelle (23.9%) and membrane (14.3%) (Supporting Information Fig. 5B ). The three most frequent molecular function categories were binding (32.3%), catalytic (29.4%) and nucleic acid-binding transcription factor activity (9.3%) (Supporting Information Fig. 5C ).
We disocovered only two proteins (47-kDa heat shock protein [HSP47/SERPINH1] and 40S ribosomal protein S23 [RSP23]) as the most overlap proteins from 60 differentially expressed proteins associated with CRC tissue with LN metastasis in Supporting Information Table 2 . According to the literature search, HSP47 expression is known to be associated with tumor progression in gastrointestinal cancers including ulcerative colitis-associated carcinomas and esophageal squamous cell carcinoma. 15, 16 In addition, the expression of HSP47 on cell surface modulates cell migration during development and invasion and metastasis in glioma.
17 RSP23 gene also overexpresses in both early and advanced stage colorectal adenocarcinomas. 18 On the other hand, although there is lack of complete functional evidence for the involvement of RSP23 in cancer, recent research reveals that RSP23 has antitumor activity to inhibit the growth of the tumors in a dose-dependent manner in vivo. 19 Collectively, we finally selected HSP47 as the most promising candidate predictive biomarker of LN metastasis in CRC patients. In fact, BLAST search (Basic Local Alignment Search Tool; http://www.uniprot.org) revealed that a specific prototypic sequence, HLAGLGLTEAIDKNK, of Serpin H1 completely overlaps with the unique peptide included in HSP47 (Supporting Information Table 2 ).
Verification of the candidate biomarker
Next, we semi-quantified HSP47 protein levels in CRC with LN, CRC without LN and CRC normal mucosa by western blot analysis to verify the result of the discovery step. HSP47 protein levels in CRC with LN metastasis were significantly higher than CRC without LN metastasis (p 5 0.0075) and adjacent normal mucosae from CRC patients (p 5 0.0008) (Figs. 1a and 1b) .
Association between HSP47 expression in cancer tissues and patients' clinicopathological characteristics IHC revealed that HSP47 expression in CRC cells was detected mainly in the cytoplasm. In contrast, HSP47 expression was undetectable in adjacent normal mucosa (Figs. 1c and 1d) . A ROC curve was generated to determine the cutoff value of HSP47 expression in CRC cells for LN metastasis (Supporting Information Fig. 6A ). Using this cutoff value (score 5 4), we classified the data into high and low groups comprising of 33.8% (53/157) and 66.2% (104/157) of patients, respectively. We next assessed the relationship between HSP47 expression and patients' clinicopathological characteristics. HSP47 expression was not associated with TNM stages or clinicopathological characteristics, except for LN metastasis (p 5 0.0122) ( Table 1 ). The expression of HSP47 in CRC with LN metastasis was significantly higher than normal mucosae (p < 0.0001) and CRC without LN metastasis (p 5 0.0099). In addition, the HSP47 expression in CRC without LN metastasis was significantly higher than that in normal mucosae (p 5 0.0016) (Fig. 1e) .
Association between the number of HSP47-positive spindle cells in cancer stroma and patients' clinicopathological characteristics
The number of HSP47-positive spindle cells of CRC with LN metastasis was significantly higher than normal mucosae (p < 0.0001) and CRC without LN metastasis (p 5 0.0002). In addition, the number of HSP47-positive spindle cells of CRC without LN metastasis was significantly higher than normal mucosae (p 5 0.0011; Figs. 1c, 1d and 1f) . A ROC curve was generated to determine the cutoff value of the number of HSP47-positive spindle cells for LN metastasis (Supporting Information Fig. 6B ). Using the value 111 (range 1-362), tumors were classified into high and low groups comprising of 31.8% (50/157) and 68.2% (107/157) of patients, respectively. The number of HSP47-positive spindle cells was significantly higher in patients with advanced T stage (p 5 0.0007), LN metastasis (p < 0.0001), lymphatic invasion (p 5 0.0003), venous invasion (p 5 0.0007), recurrence (p < 0.0001) and higher TNM stage (p < 0.0001; Table 1 ). (Table 3) .
Number of HSP47-positive spindle cells predict LN metastasis
High number of HSP47-positive spindle cells is significantly associated with poor prognosis
We determined the cutoff values of the IHC scores (score-5 9) and the number of spindle cells (score 5 104) according to the ROC curve for survival analysis, respectively Table 3 ).
Number of HSP47-positive spindle cells is significantly associated with tumor budding
We investigated the association between the number of HSP47-positive spindle cells and tumor budding in CRC. 
Association of HSP47-positive spindle cells with KRAS/ BRAF mutations and MSI
KRAS and BRAF mutation were analyzed in CRCs from 152 patients. KRAS coding mutations were detected in samples of 50 (32.9%) patients, 5 (3.3%) harbored BRAF mutations and mutations in either gene were not detected in 98 patients (64.5%). MSI and MSS were present in 9 and 142 patients, respectively. No differences in the numbers of HSP47-positive spindle cells were associated with mutations of KRAS or BRAF or with MSI (Table 1) .
Discussion
In the present study, we used iTRAQ methodology to conduct a proteomics analysis to identify a novel biomarker for CRC with LN metastasis. We identified 60 proteins associated with LN metastasis and chose to focus on HSP47 because of its function and close associations with the malignant phenotype. The confidence for this choice was confirmed by our findings that levels of expression of HSP47 in CRC tissues and the numbers of HSP47-positive spindle cells in stroma were significantly higher compared with those of adjacent normal colonic mucosa. However, not HSP expression in CRC but HSP47 positive spindle cell counts in stroma is significantly associated with tumor progression. Moreover, multivariate analysis revealed that the higher number of HSP47-positive spindle cells served as a better novel predictive biomarker for LN metastasis compared with HSP47 expression. Further, CRC patients with high numbers of HSP47-positive spindle cells had significantly earlier recurrence and poor prognosis. HSP47 localizes to the endoplasmic reticulum that interacts transiently with procollagen during the process of folding, assembly and transport of collagen from the endoplasmic reticulum in fibroblasts. The synthesis of HSP47 is related to collagen in developing tissues, cell lines and in collagen-related pathological conditions such as fibrosis. Moreover, HSP47 is associated with fibrotic disorders such as pulmonary fibrosis, glomerulosclerosis, liver cirrhosis and Crohn's disease. 20, 21 HSP47 is a component of the extracellular matrix (ECM) and is the product of SERPINH1 located on chromosome 11q13.5, which is frequently amplified in human cancers. 22 The expression of HSP47 on the cell surface following alkalization of endosomal compartments under conditions of stress suggests that HSP47 modulates cell migration during oncogenesis and subsequent tumor progression, which is characterized by invasion of surrounding tissues and metastasis. Clinically, the expression of HSP47 is increased in lung cancers, gliomas, esophageal squamous cell carcinomas and ulcerative colitis-associated carcinomas compared with normal tissues, [15] [16] [17] 23 and several studies have reported the prognostic effect of HSP47 expression in malignant disease. 16, 24, 25 These results are consistent with our study in which expression of HSP47 in CRC cells significantly increased compared with normal colonic epithelial cells, and overexpression of HSP47 in CRC associated with tumor progression and poor prognosis.
The tumor microenvironment plays a major role in modulating the metastatic capacity of cancers and determines the oncological outcome of tumors . 26, 27 Furthermore, tumor stromal cells, including fibroblasts and myofibroblasts, are essential contributors to growth, survival, invasiveness and the metastatic phenotype of neoplastic epithelial cells within these tumors, which mediate the so-called desmoplastic reaction. 28, 29 Cancer-associated fibroblasts and activated fibroblasts, in particular, play a major role in the tumor-stroma network, similar to the function of dermal fibroblasts in wound healing. Hirai et al. suggested that fibroblasts are predominant producers of stromal collagen and may therefore play an important role in the development of particular stromal changes in scirrhous carcinoma of the stomach. 30 Henry et al. described the association of elevated numbers of activated fibroblasts with decreased overall survival of patients with CRC, particularly those with metastatic tumors. 31 The expression of HSP47 in stroma plays a major role in cancer metastasis by mediating the interactions among cancer cells, fibroblasts, and the ECM. Maitra et al. reported that HSP47 is expressed in the tumor-associated stromal desmoplasia and serves as a novel marker for the diagnosis and therapy of pancreatic carcinoma. 32 Our present study demonstrates that cancer and spindle cells in the cancer stroma expressed HSP47. Moreover, the number of HSP-positive spindle cells was an independent marker for identifying LN metastasis and poor prognosis of patients with CRC. On the other hand, although the number of HSP47-positive spindle cells in cancer stroma was also significantly higher in patients with peritoneal and hepatic metastasis than in those without, predictive abilities of HSP47-positive spindle cells for peritoneal and hepatic metastasis were slightly inferior to for LN metastasis (data not shown). Therefore, our present findings suggest that the characterization of the expression pattern of HSP47 expression using an iTRAQ-proteomics approach identifies LN metastasis that mirrors HSP47-positive spindle cells in the cancer stroma and that the elevated numbers of HSP47-positive spindle cells promotes metastasis, mainly to the LNs and indicates poorer prognosis of CRC patients with curative intent.
Currently, any direct molecular biological evidence is not available to support HSP47-positive spindle cells in stroma associate with LN metastasis, resulting in early recurrence and poor prognosis. Tumor budding is defined as the presence of isolated single cells or small cell clusters scattered at invasive fronts and features the loss of glandular differentiation and cell cohesion, which are crucial for the development of a highly invasive phenotype. In addition, tumor budding is known to be the predictor of LN metastasis and serves as an indicator of the prognosis of patients with CRC. 13, 33 Interestingly, Xu et al. demonstrated that tumor budding initiates local inflammation and the production of high levels of fibroblast growth factor-2 by neutrophil and stromal spindle cells that express HSP47, leading to fibrosis. 34 We also showed that tumor budding grades correlated significantly with number of fibroblasts that expressed HSP47 in the cancer stroma. Collectively, we suggest that tumor budding increases HSP47-positive spindle cell in cancer stroma. In other words, the counts of HSP47-positive spindle cells in cancer stroma might be a surrogate marker of tumor budding, and serve as a predictive biomarker of LN metastasis, early recurrence and poor progress of CRC.
Despite that the number of HSP47-positive spindle cells in the cancer stroma appear to be a promising biomarker strategy for prediction of LN metastasis, the data shown in the current study have some limitations as this was a retrospective, single-institution, and relatively small-sample study. In addition, follow-up time of patients in this study was relatively short, consequently only number of HSP47-positive spindle cells were selected as significant indicators of poor OS in univariate analysis. Therefore, we believe that future prospective studies with a large cohort are required to further highlight the clinical usefulness of HSP47-positive spindle cells in CRC.
In conclusion, to the best of our knowledge, we for the first time show that the number of HSP47-positive spindle cells in the cancer stroma of patients with CRC serve as a novel predictive biomarker of LN metastasis, early recurrence and poor prognosis. Thus, evaluating the number of HSP47 positive-spindle cells preoperatively may be valuable for planning the treatment of patients with CRC. However, for eventual clinical application, further prospective studies are needed to validate our preliminary results using preoperative biopsy samples form CRC patients in future.
